Clinical ProgressCelldex announced positive topline results from its Phase 2 clinical study evaluating barzolvolimab in chronic inducible urticaria, meeting its primary endpoint.
Market OpportunityBarzolvolimab has a viable opportunity to differentiate in the competitive market as a mast cell depleting agent for atopic dermatitis.
Product EfficacyBarzolvolimab is seen as the best-in-class anti-cKIT antibody, showing stellar efficacy in CSU patients with a consistent and acceptable safety profile.